Progesterone plays two major roles during menopause: it protects the uterine lining from the cancer-promoting effects of estrogen therapy, and it independently helps with sleep and hot flashes. If you have a uterus and take estrogen for menopause symptoms, progesterone isn’t optional. It’s a required partner that keeps estrogen from overstimulating the endometrium. But progesterone also has effects beyond the uterus that make it relevant even outside its traditional protective role.
Why Estrogen Therapy Requires Progesterone
Estrogen, taken alone, stimulates the uterine lining to grow. Without something to counteract that growth, the lining can thicken abnormally, a condition called endometrial hyperplasia, which raises the risk of uterine cancer over time. Progesterone works against estrogen in the uterus by changing enzyme activity and reducing the number of estrogen receptors in endometrial tissue. This effectively puts the brakes on estrogen-driven growth.
Taking progesterone for at least 10 to 14 days per month, or continuously at a lower dose, prevents this dangerous buildup. A dose of 300 mg for 14 days per cycle is considered effective for endometrial cancer prevention. The 2022 position statement from the North American Menopause Society is clear: any woman with an intact uterus who uses systemic estrogen therapy needs a progestogen alongside it. The one exception is low-dose vaginal estrogen used only for vaginal dryness or urinary symptoms, which has minimal absorption into the bloodstream and doesn’t require progesterone.
How It Helps With Sleep
One of progesterone’s most noticeable effects has nothing to do with the uterus. When your body processes oral progesterone, it produces metabolites that act on the same brain receptors targeted by sleep and anti-anxiety medications. These receptors, part of the GABA system, are the brain’s main “calm down” pathway. The effect is sedating enough that progesterone is typically prescribed at bedtime.
In a placebo-controlled trial of 133 postmenopausal women taking 300 mg of oral progesterone at bedtime, sleep recordings showed a measurable reduction in wakefulness compared to placebo. This sedating quality is one reason many women notice they sleep better on progesterone, and it’s also why the timing of the dose matters. Taking it in the morning would leave you drowsy during the day.
Effects on Hot Flashes
Progesterone can reduce hot flashes on its own, though the evidence is more mixed than for estrogen. In a randomized trial of 133 women in early menopause, 300 mg of oral progesterone at bedtime reduced both the frequency and severity of hot flashes more than placebo. A second trial in 189 perimenopausal women showed a similar trend, but the difference didn’t reach statistical significance.
This means progesterone alone is not as reliable for hot flashes as estrogen is. But for women who can’t take estrogen, or who are still in perimenopause and mainly need cycle regulation alongside symptom relief, progesterone offers a real, if modest, benefit. It’s most useful when hot flashes are mild to moderate rather than severe.
Micronized Progesterone vs. Synthetic Progestins
Not all forms of progesterone carry the same risks. This distinction matters most when it comes to breast cancer. The term “progestogen” covers both natural (micronized) progesterone and synthetic versions like medroxyprogesterone acetate (MPA). Research over the past two decades has shown these are not interchangeable in terms of safety.
In the Women’s Health Initiative trial, the combination of estrogen with synthetic MPA increased breast cancer risk by 28% after more than 20 years of follow-up. But studies looking specifically at micronized progesterone tell a different story. A large British case-control study found that estrogen combined with synthetic progestins raised breast cancer risk by 28%, while estrogen combined with micronized progesterone showed no increased risk at all. A French population study found the same pattern: synthetic progestins raised risk by about 40%, while micronized progesterone did not. A third case-control study of over 1,500 women found that synthetic progestin therapy nearly doubled breast cancer risk, while micronized progesterone was again associated with no increase.
This is why many clinicians now prefer prescribing micronized progesterone over synthetic alternatives when endometrial protection is the goal. The NAMS position statement acknowledges that breast cancer risk is greater with regimens containing MPA specifically, and considers the overall risk with hormone therapy to be rare.
What It Doesn’t Do to Your Heart
A common concern with any hormone therapy is cardiovascular impact. A three-month randomized trial of 300 mg daily progesterone in healthy postmenopausal women found reassuring results on most fronts. Blood pressure, heart rate, total cholesterol, LDL cholesterol, triglycerides, and fasting glucose all remained comparable to placebo. Cardiovascular risk scores stayed low throughout the study.
The one exception was HDL cholesterol (the “good” cholesterol), which dropped slightly during progesterone therapy. The clinical significance of this small decrease is uncertain, but it’s worth noting. Overall, progesterone appears to be metabolically neutral for most women over a short treatment period, neither improving nor worsening cardiovascular risk markers in any major way.
Cyclical vs. Continuous Dosing
Progesterone can be taken on two different schedules, and each comes with trade-offs. In cyclical dosing, you take progesterone for 10 to 14 days each month alongside daily estrogen. This mimics a natural menstrual cycle pattern and typically causes a withdrawal bleed at the end of each progesterone phase, similar to a period. For women who recently entered menopause and are used to having periods, this schedule can feel more familiar.
In continuous dosing, you take a lower dose of progesterone every day alongside daily estrogen. The goal is to avoid monthly bleeding entirely. In practice, irregular spotting or light bleeding is common in the first six months but usually resolves. Continuous dosing is generally preferred for women who are several years past their last period and don’t want monthly bleeds.
The standard dose for cyclical therapy is 300 mg at bedtime for 14 days per month. For continuous use, 100 to 200 mg daily is typical. If breakthrough bleeding persists on a cyclical schedule, the dose can sometimes be increased to 400 mg, or a switch to daily progesterone for three months can help stabilize the lining.
Who Might Not Need It
If you’ve had a hysterectomy, you don’t have a uterus to protect, so the primary reason for progesterone disappears. Most women without a uterus take estrogen alone. The sleep and hot flash benefits of progesterone still exist, but they aren’t strong enough on their own to justify adding a second hormone for most women in this group.
Women using only low-dose vaginal estrogen for dryness, irritation, or urinary symptoms also don’t need progesterone. These local preparations deliver estrogen directly to vaginal tissue with minimal absorption into the bloodstream, so the uterine lining isn’t significantly stimulated.